CytomX, AbbVie deal

CytomX and AbbVie partnered to co-develop and co-commercialize Probody drug conjugates against transferrin receptor ( TFRC; TFR).

Read the full 170 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE